IdrA

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 1, 2021

EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.

Key Points: 
  • EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.
  • Since September 30, 2020, the following corporate updates were announced:
    The Company closed a second tranche under its April 7, 2020 securities purchase agreement for additional aggregate gross proceeds of $5.0 million.
  • The Company appointed Daniel Soland as Senior Vice President and Chief Operating Officer as of January 4, 2021.
  • R. Clayton Fletcher, Senior Vice President of Business Development and Strategic Planning, retired from the Company as of December 31, 2020.

Idera Pharmaceuticals to Present at Upcoming Conferences

Retrieved on: 
Monday, January 11, 2021

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.

Key Points: 
  • EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.
  • Were looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.
  • We have confidence that this is the year Idera will deliver on its long history of innovative science and begin to turn that history into a business reality.
  • Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements.

Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 4, 2020

EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020.

Key Points: 
  • EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020.
  • Idera meaningfully advanced its clinical pipeline and strengthened its financial resources in the first part of 2020.
  • Further encouraged by data from ILLUMINATE-204, which we reported in the second quarter, we continue to work diligently against our timelines for ILLUMINATE-301.
  • The Company anticipates that its current cash, cash equivalents, and short-term investments will fund our operations into the second quarter of 2021.

Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, April 30, 2020

EXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2020.

Key Points: 
  • EXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2020.
  • Im proud of what Idera has accomplished since the beginning of the year, despite the worldwide impact of the COVID-19 pandemic.
  • The Company anticipates that its current cash, cash equivalents, and short-term investments will fund our operations into the second quarter of 2021.
  • Final data from the trial to be submitted for presentation at a medical conference in the second half of 2020.

IDRA EAC-South Assists Virginia Commission on African American History Education in the Commonwealth

Retrieved on: 
Monday, October 28, 2019

CHARLOTTESVILLE, Va., Oct. 28, 2019 /PRNewswire/ -- More than 30 members of the new Virginia Commission on African American History Education in the Commonwealth were sworn in today.

Key Points: 
  • CHARLOTTESVILLE, Va., Oct. 28, 2019 /PRNewswire/ -- More than 30 members of the new Virginia Commission on African American History Education in the Commonwealth were sworn in today.
  • The governor's office asked the IDRA EAC-South to assist the commission's work sessions and report creation between now and July 2020, when the commission's recommendations will be submitted to Virginia Governor Ralph Northam.
  • "The IDRA EAC-South is honored to facilitate this historic commission," said Dr. Paula Johnson, director of the IDRA EAC-South.
  • "Virginia is embarking on a courageous and powerful initiative that will ensure that students in the Commonwealth will understand that African American history is U.S. history.

Supporting Students in the Wake of Violence - Livestream Event

Retrieved on: 
Thursday, September 19, 2019

Intercultural Development Research Association is an independent, non-profit organization, led by Celina Moreno, J.D.

Key Points: 
  • Intercultural Development Research Association is an independent, non-profit organization, led by Celina Moreno, J.D.
  • Our mission is to achieve equal educational opportunity for every child through strong public schools that prepare all students to access and succeed in college.
  • IDRA strengthens and transforms public education by providing dynamic training; useful research, evaluation, and frameworks for action; timely policy analyses; and innovative materials and programs.
  • We build bridges among administrators, teachers, parents, students and community members so that all stakeholders can find that common higher ground where all students will benefit regardless of race, sex or national origin.